Objective: To investigate the mRNA and protein levels of calpain small subunit-1 (Capn4) in human clear cell renal cell carcinoma (ccRCC), to analyse the relationship between Capn4 mRNA level and pathological stage of ccRCC, and to examine the potential of Capn4 as a prognostic factor in ccRCC. Methods: mRNA and protein levels of Capn4 were measured in pairs of tumour tissues and matched adjacent nontumour tissue obtained from patients with ccRCC by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting, respectively. Associations of the mRNA level of Capn4 with pathological tumour stage and the overall survival of ccRCC patients were also analysed. Results: Capn4 mRNA and protein level were significantly higher in ccRCC tumour tissues compared with adjacent nontumour tissues as assessed by qRT-PCR and Western blotting, respectively. Higher Capn4 mRNA levels were observed in patients with more advanced pathological stage of ccRCC and were also associated with decreased overall survival of patients with ccRCC. Conclusions: The findings from this study indicate that Capn4 has the potential to be an independent prognostic indicator for ccRCC.
Introduction
Renal cell carcinoma (RCC, also known as hypernephroma) is a common solid lesion that develops in the lining of adult kidney tubules. 1 It represents 2-3% of all adult cancers and approximately 80% of primary renal cancers. 2 RCC is the third most prevalent urological cancer after prostate and bladder cancers and the mortality rate is >40%. 3 It has been estimated that 65 150 new cases of renal cancer will be diagnosed in 2013, resulting in approximately 13 680 deaths, 4 and the vast majority of these cases will be caused by RCC. Five-year survival rates for each stage of RCC have been estimated to be: stage I, 93%; stage II, 65%; stage III, 53%; stage IV, 27%. 5 Since RCC represents a heterogeneous group of tumours, consisting of clear cell, papillary, chromophobe, collecting duct and unclassified tumours, it poses a considerable clinical challenge. 6 Clear cell RCC (ccRCC) is the most common subtype (75-80%) of RCC. 2 It is associated with unpredictable clinical outcome because it can demonstrate longterm survival in the presence of metastases, late recurrence and spontaneous regression. 5, 7 Several different parameters including tumour grade, DNA ploidy and nuclear morphometry have been employed to predict prognosis of RCC but a reliable marker has not yet been established. [7] [8] There is a clinical need to identify prognostic biomarkers with high specificity and sensitivity for RCC in order to improve the understanding of its molecular pathogenesis and facilitate the discovery of novel therapeutic targets.
The calpains are a highly conserved family of calcium-dependent, non-lysosomal cysteine proteases that catalyse regulated proteolysis of many specific substrates. 9 The mammalian calpains consist of 14 family members, of which micro (m)-calpain and milli (m)-calpain are the two most extensively studied isoforms. [10] [11] [12] Both m-calpain and m-calpain are heterodimers with a distinct catalytic subunit of 80 kDa (calpain-1 large subunit, encoded by CAPN1 for m-calpain and calpain-2 large subunit, encoded by CAPN2 for m-calpain) and a common regulatory subunit of 28 kDa (calpain small subunit-1 [Capn4], encoded by CAPN4). 13 Within the calpain family, some isoforms are ubiquitously expressed, such as m-calpain and m-calpain, while others have a more restricted expression: for example, calpain-8 and calpain-9 are exclusively expressed in the stomach mucosa and digestive tract. 13 Although the exact physiological roles of the calpain isoforms remain unclear, they have been implicated in various cellular processes such as cell motility, 14 programmed cell death 15 and cell cycle progression. 16, 17 It has been suggested that cellular transformation leads to enhanced calpain activity, which promotes local tumour invasion and peripheral metastasis through the proteolysis of local adhesion proteins including focal adhesion kinase and talin. 13, [18] [19] [20] The regulatory subunit, Capn4, plays a critical role in maintaining calpain activity; Capn4 ablation in Capn4-knockout mice is lethal at the embryonic stage, with animals demonstrating no detectable calpain activity. 21, 22 In addition, recent studies have revealed that Capn4 is increased in both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and is associated with poor prognosis; Capn4 knockdown inhibits the migration and invasion abilities of both HCC and ICC cells. [23] [24] [25] The role of Capn4 in RCC has not, as yet, been extensively studied.
The present study was undertaken to examine the mRNA and protein levels of Capn4 in clinical ccRCC tissues obtained from patients undergoing partial or radical nephrectomy. In addition, the relationship between Capn4 levels and clinicopathological features of ccRCC were examined and the prognostic value of Capn4 for postresection survival in ccRCC patients was determined.
Materials and methods

Tissue samples
Renal cell carcinoma tissue and adjacent nontumour tissue (!5 mm from the carcinoma tissue) were harvested from patients undergoing partial or radical nephrectomy at the Department of Urology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China between October 2000 and September 2006. No further inclusion or exclusion criteria were defined for this study. Portions of the tissue samples were immediately sent for pathological inspection to confirm the presence (tumour tissue containing >80% tumour cells) or absence (normal tissue) of ccRCC. Staging of ccRCC was performed using the American Joint Committee on Cancer (AJCC) staging manual. 26 The remainder of the tissue samples was immediately frozen in liquid nitrogen and stored for a mean of 6 months prior to analysis.
The study protocol was approved by the ethics committee of the Third Affiliated Hospital of Soochow University and all participating patients provided written informed consent.
RNA isolation and quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Total RNA was isolated from ccRCC tissues and adjacent nontumour tissues (50-100 mg tissue) using TRIzol Õ reagent (Invitrogen Corp., Carlsbad, CA, USA). qRT-PCR was performed as described previously. 27 Briefly, reverse transcription was performed using SuperScript TM II RT (Invitrogen Corp.) as per the manufacturer's protocol. TaqMan Õ gene expression assays (Applied Biosystems, Foster City, CA, USA) were used to quantify Capn4 mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as an internal control. The primer sequences for qRT-PCR were as follows (Invitrogen Corp.):
CAPN4 forward, 5 0 -TCCGACGCTACTCAGATGAAAGT-3 0 and reverse, 5 0 -GATTTGTCCAGT GCCATCTTTGT-3 0 ; GAPDH forward, 5 0 -TCCACCACCCTGTTGCTGTA-3 0 and reverse, 5 0 -ACCACAGTCCATGCCAT CAC-3 0 . The PCR reactions were performed on a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) in duplicate in a 10 ml volume containing 5 ml Universal PCR Master Mix (Applied Biosystems), 0.5 ml TaqMan Õ assay and 4.5 ml diluted cDNA (50 ng reversetranscribed RNA). PCR cycling conditions were 50 C for 2 min, 95 C for 10 min and 40 cycles of 95 C for 15 s and 60 C for 1 min. PCR products were visualized on 1.2% agarose, purified and then verified by sequencing. The relative expression level of Capn4 mRNA was normalized with GAPDH expression level and calculated using the 2 ÀÁÁCt method. 28 
Western blot analysis
Protein was extracted from frozen ccRCC tissues and adjacent nontumour tissues using the Whole Protein Extraction Kit (Fermentas Life Science, Glen Burnie, MD, USA) as per the manufacturer's instructions. The microplate bicinchoninic assay (BCA) protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA) was used according to the manufacturer's instructions to determine protein concentration. Western blot analysis was carried out as described previously. 29 
Statistical analyses
All statistical analyses were carried out using SPSS Õ statistical software, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . Data are presented as the mean AE standard deviation (SD) from at least three independent experiments. Paired samples t-test was performed to analyse significant differences between the ccRCC and adjacent nontumour tissue. Spearman's rank correlation test was carried out to determine the relationship between Capn4 expression level and tumour progression status. Capn4 mRNA levels were considered to be significantly increased if the calculated fold-change was more than 0.5 in tumour tissue compared with the matched adjacent nontumour tissue. The overall survival rates were calculated by the Kaplan-Meier method , and the difference in survival was compared with the log-rank test. The Cox proportional hazards regression model was used for univariate and multivariate analyses to assess the effects of the clinicopathological variables and Capn4 mRNA expression levels on overall survival. A P-value of <0.05 was considered statistically significant.
Results
Paired tissue samples (tumour tissue and matched adjacent nontumour tissue) were collected from 40 patients with ccRCC. Patient and tumour characteristics are shown in Table 1 . As shown in Figure 1 , the mRNA level of Capn4 in ccRCC tumour samples was statistically significantly higher than in nontumour tissue samples (P ¼ 0.013).
In all 40 paired tissue samples evaluated, the protein band intensities of Capn4 in ccRCC tumour tissue were visually stronger compared with adjacent nontumour tissues. Representative results for the first four pairs of tissue samples are shown in Figure 2a . As shown in Figure 2b , protein levels of Capn4 in ccRCC tumour tissues were significantly increased compared with levels determined in adjacent nontumour tissues (P ¼ 0.005).
Capn4 mRNA levels were correlated with the presence of ccRCC and tumour stage: Capn4 mRNA was increased in 77.5% (31/40) of patients with ccRCC. High levels of Capn4 mRNA were observed in 61.1% (11/18) of patients with low primary tumour stages (pT1 þ pT2) and 90.9% (20/22) of patients with high primary tumour stages (pT3 þ pT4) ( Figure 3 ).
Kaplan-Meier analysis revealed that higher levels of Capn4 mRNA in ccRCC tissues were significantly associated with decreased overall survival (P ¼ 0.006; Figure 4 ).
Univariate analysis using a Cox proportional hazards model to evaluate the potential of using Capn4 mRNA expression level as a prognostic marker for ccRCC patients after surgery showed that both Capn4 G3  pT3a  16  M  63  G2  pT3a  17  F  63  G3  pT3b  18  M  63  G2  pT3a  19  F  47  G1  pT2a  20  F  36  G2  pT4  21  M  75  G3  pT3b  22  F  50  G2  pT3a  23  M  45  G1  pT1a  24  F  60  G2  pT3b  25  F  71  G2  pT3b  26  F  65  G3  pT1b  27  M  63  G3  pT2b  28  M  47  G2  pT3b  29  F  67  G4  pT1b  30  F  45  G3  pT3a  31  M  66  G3  pT2a  32  M  45  G1  pT1a  33  M  45  G3  pT3b  34  F  72  G4  pT4  35  M  60  G2  pT2b  36  M  71  G2  pT3b  37  F  65  G3  pT3a  38  F  63  G3  pT3b  39  F  47  G2  pT2a  40  M  66  G3  pT1b a Fuhrman grading schema of renal cell carcinoma is based on the microscopic morphology of a neoplasm with haematoxylin and eosin staining; 31 four nuclear grades (1-4) are defined in order of increasing nuclear size, irregularity and nucleolar prominence. b pT1a: primary tumour 4 cm in greatest dimension, limited to the kidney; pT1b: primary tumour >4 cm but not >7 cm in greatest dimension, limited to the kidney; pT2a: tumour >7 cm but 10 cm in greatest dimension, limited to the kidney; pT2b: primary tumour >10 cm, limited to the kidney; pT3a: tumour grossly extends into the renal vein or its segmental, muscle-containing, branches, or tumour invades perirenal and/ or renal sinus fat but not beyond Gerota's fascia; pT3b: primary tumour grossly extends into the vena cava below the diaphragm; pT4: primary tumour invades beyond Gerota's fascia. 26 overexpression (P ¼ 0.009) and primary tumour stage (P ¼ 0.010) were the prime variables for ccRCC prognosis ( Table 2) . After adjusting for clinicopathologic variables, Capn4 overexpression (P ¼ 0.013) and primary tumour stage (P ¼ 0.008) remained significantly correlated with the prognosis of ccRCC patients ( Table 2 ). 
Discussion
Renal cell carcinoma is the most common malignant primary tumour in human kidney cancer. Improvements in disease therapy have led to disease remission in many patients but the overall prognosis remains unsatisfactory. One of the essential factors governing prognosis in patients with RCC is the tumour stage at the time of diagnosis.
Patients with RCC who have tumours confined to the kidney have the best prognosis. 30 There is an important clinical need to identify biomarkers that can assist in the 
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Calpains are a family of intracellular cysteine proteases, with both ubiquitous and tissue-specific isoforms. 13 The prototypical calpain is composed of an isoformspecific large subunit and a common small subunit (Capn4). 13 Capn4 was dramatically increased in metastatic tissues compared with nonmetastatic tissues from patients with HCC in a previous study. 23 It was also shown that increases in Capn4 were correlated with the invasive phenotype of HCC and that Capn4 may represent a potential prognostic factor for tumour recurrence and survival in patients with HCC. 23 In addition, previous studies have demonstrated the ectopic expression of Capn4 in patients with ICC, a primary malignant liver neoplasm secondary to HCC, and the association of increased Capn4 with lymphatic metastasis and tumour-node-metastasis stage of ICC. 25 The mechanisms by which Capn4 promotes metastasis and invasion in liver neoplasms has been studied; it has been demonstrated that Capn4 and osteopontin interact with each other and promote cell migration through the nuclear factor-kB pathway. 24 The present study investigated the role of Capn4 in ccRCC. Compared with matched adjacent nontumour tissues, the levels of Capn4 mRNA and protein were aberrantly high in the tumour tissue of patients with ccRCC. Furthermore, Capn4 mRNA levels appeared to be correlated with the pathological stage of ccRCC, with higher Capn4 levels observed in patients with high primary tumour stages compared with patients with low primary tumour stages. In addition, higher levels of Capn4 mRNA were found to be associated with decreased overall survival in patients with ccRCC. Both univariate and multivariate analysis indicated that Capn4 expression status is an independent prognostic indicator for ccRCC. These data are consistent with previous findings in other tumour types [23] [24] [25] and indicate that Capn4 could be a potential prognostic marker in ccRCC.
In conclusion, the present study has shown for the first time that Capn4 mRNA and protein are increased in ccRCC tissues and that higher Capn4 levels are associated with advanced clinical tumour stage and shorter overall survival. The precise role of Capn4 in ccRCC development and progression, however, remains to be elucidated and further investigations in cell and animal models are in progress.
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